Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Neuromodulation. 2015 Dec 8;19(1):85–90. doi: 10.1111/ner.12370

Table 1. Patient Demographics.

All Percutaneous SCS Paddle SCS
Overall - no. (%) 8,326 (100.0) 5,458 (65.55) 2,868 (34.45)
Female - no.(%) 5,142 (61.76) 3,417 (62.61) 1,725 (60.15)
Age - mean (SD) 54.4 (13.19) 54.5 (13.33) 54.2 (12.92)
Insurance - no. (%)
COMMERCIAL 5,577 (66.98) 3,713 (68.03) 1,864 (64.99)
MEDICAID 1,125 (13.51) 655 (12.00) 470 (16.39)
MEDICARE 1,624 (19.51) 1,090 (19.97) 534 (18.62)
Follow Up Days - mean (SD) 703.4 (584.06) 724.6 (592.23) 663.0 (566.10)
Charlson Comorbidity Index - no. (%)
0 7,709 (92.59) 5,125 (93.90) 2,584 (90.10)
1 491 (5.90) 250 (4.58) 241 (8.40)
2 121 (1.45) 80 (1.47) 41 (1.43)
3 or higher 5 (0.06) 3 (0.05) 2 (0.07)